The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits

K. Y. Hsu, D. J. Song, Y. Ho

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

During the past few years, acetylation polymorphism has been shown to be a proven, established fact, and N-acetyltransferase, an enzyme that transfers an acetyl group to the substrate, has been recognized as the main factor in acetylation polymorphism. In a recent study, a significant difference between the acetylation phenotype and plasma pyruvic acid (PA) concentration in rabbits was found. In this report, the influence of PA on the pharmacokinetics of sulphadiazine (SDZ), a drug that has been used in pharmacogenetic studies of acetylation, was studied. By using a loading dose of 300 mg kg-1, and an infusion rate of 7·5 mg min-1 kg-1 of PA, the concentration of PA reached a steady state (C(ss)≃ 100 μg mL-1) in 30 min. During PA infusion in rapid-acetylation rabbits, no significant changes were found in any of the pharmacokinetic parameters for SDZ. However, differences were found in the β half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the β half-life decreased from 115.74 ± 12.47min to 62.96 ± 4.36 min (p <0.001); AUC decreased from 10617.38 ± 1179.81 μg min mL-1 to 6217.14 ± 391.32 μg min mL-1 (p <0.001); clearance increased from 0.0044 ± 0.0008 Lmin-1 kg-1 to 0.0068 ± 0.0007 Lmin-1 kg-1 (p <0.001); and k10 increased from 0.0090 ± 0.0009 min-1 to 0.0193 ± 0.0028 min-1 (p <0.005). The reason for this may be that PA influences the elimination of SDZ in slow-acetylation rabbits.

Original languageEnglish
Pages (from-to)233-244
Number of pages12
JournalBiopharmaceutics and Drug Disposition
Volume16
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Sulfadiazine
Acetylation
Pyruvic Acid
Pharmacokinetics
Rabbits
Area Under Curve
Half-Life
Acetyltransferases
Phenotype
Enzymes
Pharmaceutical Preparations

Keywords

  • acetylation
  • pharmacokinetics
  • phenotype
  • pyruvic acid
  • sulphadiazine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits. / Hsu, K. Y.; Song, D. J.; Ho, Y.

In: Biopharmaceutics and Drug Disposition, Vol. 16, No. 3, 1995, p. 233-244.

Research output: Contribution to journalArticle

@article{c4ef1c326bcf40cd9813dc581efc0013,
title = "The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits",
abstract = "During the past few years, acetylation polymorphism has been shown to be a proven, established fact, and N-acetyltransferase, an enzyme that transfers an acetyl group to the substrate, has been recognized as the main factor in acetylation polymorphism. In a recent study, a significant difference between the acetylation phenotype and plasma pyruvic acid (PA) concentration in rabbits was found. In this report, the influence of PA on the pharmacokinetics of sulphadiazine (SDZ), a drug that has been used in pharmacogenetic studies of acetylation, was studied. By using a loading dose of 300 mg kg-1, and an infusion rate of 7·5 mg min-1 kg-1 of PA, the concentration of PA reached a steady state (C(ss)≃ 100 μg mL-1) in 30 min. During PA infusion in rapid-acetylation rabbits, no significant changes were found in any of the pharmacokinetic parameters for SDZ. However, differences were found in the β half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the β half-life decreased from 115.74 ± 12.47min to 62.96 ± 4.36 min (p <0.001); AUC decreased from 10617.38 ± 1179.81 μg min mL-1 to 6217.14 ± 391.32 μg min mL-1 (p <0.001); clearance increased from 0.0044 ± 0.0008 Lmin-1 kg-1 to 0.0068 ± 0.0007 Lmin-1 kg-1 (p <0.001); and k10 increased from 0.0090 ± 0.0009 min-1 to 0.0193 ± 0.0028 min-1 (p <0.005). The reason for this may be that PA influences the elimination of SDZ in slow-acetylation rabbits.",
keywords = "acetylation, pharmacokinetics, phenotype, pyruvic acid, sulphadiazine",
author = "Hsu, {K. Y.} and Song, {D. J.} and Y. Ho",
year = "1995",
doi = "10.1002/bdd.2510160308",
language = "English",
volume = "16",
pages = "233--244",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - The influence of pyruvic acid on the pharmacokinetics of sulphadiazine in rabbits

AU - Hsu, K. Y.

AU - Song, D. J.

AU - Ho, Y.

PY - 1995

Y1 - 1995

N2 - During the past few years, acetylation polymorphism has been shown to be a proven, established fact, and N-acetyltransferase, an enzyme that transfers an acetyl group to the substrate, has been recognized as the main factor in acetylation polymorphism. In a recent study, a significant difference between the acetylation phenotype and plasma pyruvic acid (PA) concentration in rabbits was found. In this report, the influence of PA on the pharmacokinetics of sulphadiazine (SDZ), a drug that has been used in pharmacogenetic studies of acetylation, was studied. By using a loading dose of 300 mg kg-1, and an infusion rate of 7·5 mg min-1 kg-1 of PA, the concentration of PA reached a steady state (C(ss)≃ 100 μg mL-1) in 30 min. During PA infusion in rapid-acetylation rabbits, no significant changes were found in any of the pharmacokinetic parameters for SDZ. However, differences were found in the β half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the β half-life decreased from 115.74 ± 12.47min to 62.96 ± 4.36 min (p <0.001); AUC decreased from 10617.38 ± 1179.81 μg min mL-1 to 6217.14 ± 391.32 μg min mL-1 (p <0.001); clearance increased from 0.0044 ± 0.0008 Lmin-1 kg-1 to 0.0068 ± 0.0007 Lmin-1 kg-1 (p <0.001); and k10 increased from 0.0090 ± 0.0009 min-1 to 0.0193 ± 0.0028 min-1 (p <0.005). The reason for this may be that PA influences the elimination of SDZ in slow-acetylation rabbits.

AB - During the past few years, acetylation polymorphism has been shown to be a proven, established fact, and N-acetyltransferase, an enzyme that transfers an acetyl group to the substrate, has been recognized as the main factor in acetylation polymorphism. In a recent study, a significant difference between the acetylation phenotype and plasma pyruvic acid (PA) concentration in rabbits was found. In this report, the influence of PA on the pharmacokinetics of sulphadiazine (SDZ), a drug that has been used in pharmacogenetic studies of acetylation, was studied. By using a loading dose of 300 mg kg-1, and an infusion rate of 7·5 mg min-1 kg-1 of PA, the concentration of PA reached a steady state (C(ss)≃ 100 μg mL-1) in 30 min. During PA infusion in rapid-acetylation rabbits, no significant changes were found in any of the pharmacokinetic parameters for SDZ. However, differences were found in the β half-life, AUC, clearance, and k10 of SDZ in slow acetylators: the β half-life decreased from 115.74 ± 12.47min to 62.96 ± 4.36 min (p <0.001); AUC decreased from 10617.38 ± 1179.81 μg min mL-1 to 6217.14 ± 391.32 μg min mL-1 (p <0.001); clearance increased from 0.0044 ± 0.0008 Lmin-1 kg-1 to 0.0068 ± 0.0007 Lmin-1 kg-1 (p <0.001); and k10 increased from 0.0090 ± 0.0009 min-1 to 0.0193 ± 0.0028 min-1 (p <0.005). The reason for this may be that PA influences the elimination of SDZ in slow-acetylation rabbits.

KW - acetylation

KW - pharmacokinetics

KW - phenotype

KW - pyruvic acid

KW - sulphadiazine

UR - http://www.scopus.com/inward/record.url?scp=0028959614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028959614&partnerID=8YFLogxK

U2 - 10.1002/bdd.2510160308

DO - 10.1002/bdd.2510160308

M3 - Article

C2 - 7787135

AN - SCOPUS:0028959614

VL - 16

SP - 233

EP - 244

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 3

ER -